2,105
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Effectiveness of lymphoplasmapheresis compared with therapeutic plasma exchange for thrombotic thrombocytopenic purpura: a retrospective evaluation

, , , &

Reference

  • Terrell DR, Williams LA, Vesely SK, et al. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. JTH. 2005;3(7):1432–1436.
  • Scully M, Yarranton H, Liesner R, et al. Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features. Br J Haematol. 2008;142(5):819–826.
  • Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339(22):1585–1594.
  • Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian apheresis study group. N Engl J Med. 1991;325(6):393–397.
  • Dervenoulas J, Tsirigotis P, Bollas G, et al. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases. Ann Hematol. 2000;79(2):66–72.
  • Vesely SK, George JN, Lammle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102(1):60–68.
  • Bandarenko N, Brecher ME. United States thrombotic thrombocytopenic purpura apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher. 1998;13(3):133–141.
  • Tuncer HH, Oster RA, Huang ST, et al. Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience. Transfusion. 2007;47(1):107–114.
  • O’Connor NT, O’Shea MJ, Hill LF. Vincristine for thrombotic thrombocytopenic purpura. Lancet. 1992;340(8817):490.
  • Durand JM, Lefevre P, Kaplanski G, et al. Ineffectiveness of high-dose intravenous gammaglobulin infusion in thrombotic thrombocytopenic purpura. Am J Hematol. 1993;42(2):234.
  • Udvardy M, Rak K. Cyclophosphamide for chronic relapsing thrombotic thrombocytopenic purpura. Lancet. 1990;336(8729):1508–1509.
  • Luo MC, Wang WF, Yin WF, et al. Clinical efficacy and mechanism of lymphoplasma exchange in the treatment of Guillain-Barre syndrome. Cell. Mol. Biol. (Noisy-le-grand). 2017;63(10):106–115.
  • Scully M, Hunt BJ, Benjamin S, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158(3):323–335.
  • Yao L-q, Jin Z-c, Ji M-s, et al. [Effect of continuous renal replacement therapy started at different time on patients with multiple organ dysfunction syndrome]. Zhonghua yi xue za zhi. 2011;91(24):1663–1667.
  • Möse JR. [Influence of plasmaphoresis on total and T-lymphocyte count (author’s transl)]. Blut. 1978;36(3):175–178.
  • Paton E, Baldwin IC. Plasma exchange in the intensive care unit: a 10 year retrospective audit. Aust Crit Care. 2014;27(3):139–144.
  • Becerra E, Scully MA, Leandro MJ, et al. Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura. Clin Exp Immunol. 2015;179(3):414–425.
  • RA. G. (1978). Biology of the immune response, Immunologic Disorders in Infants and Children. Edited by R Stiehm and VA Fulginiti Philadelphia, W B Saunders Co.
  • Starzl TE, Weil3rd R, Koep LJ, et al. Thoracic duct fistula and renal transplantation. Ann Surg. 1979;190(4):474–486.